IL127129A - Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared - Google Patents
Method for preparation of progesterone tablets for vaginal delivery and tablets so preparedInfo
- Publication number
- IL127129A IL127129A IL12712998A IL12712998A IL127129A IL 127129 A IL127129 A IL 127129A IL 12712998 A IL12712998 A IL 12712998A IL 12712998 A IL12712998 A IL 12712998A IL 127129 A IL127129 A IL 127129A
- Authority
- IL
- Israel
- Prior art keywords
- mixture
- micronized progesterone
- mixing
- lubricant
- progesterone
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 177
- 238000000034 method Methods 0.000 title claims abstract description 51
- 229960003387 progesterone Drugs 0.000 title claims abstract description 32
- 239000000186 progesterone Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 6
- 208000034423 Delivery Diseases 0.000 title description 5
- 230000009677 vaginal delivery Effects 0.000 title description 5
- 229960001207 micronized progesterone Drugs 0.000 claims abstract description 113
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000003085 diluting agent Substances 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 238000005056 compaction Methods 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 13
- 238000009736 wetting Methods 0.000 claims abstract description 11
- 230000009885 systemic effect Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 107
- 239000000314 lubricant Substances 0.000 claims description 52
- 239000000945 filler Substances 0.000 claims description 30
- 239000011148 porous material Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229940069328 povidone Drugs 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 3
- 235000009973 maize Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 235000012015 potatoes Nutrition 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000011008 sodium phosphates Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229910002019 Aerosil® 380 Inorganic materials 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 101100010343 Drosophila melanogaster lobo gene Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 229940109111 progesterone vaginal tablet Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12712998A IL127129A (en) | 1998-11-18 | 1998-11-18 | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| EP11166346A EP2386291A1 (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparing same |
| ES99972096T ES2390959T3 (es) | 1998-11-18 | 1999-11-17 | Comprimidos de administración vaginal que contienen progesterona y procedimiento para preparar los mismos |
| JP2000582018A JP4667601B2 (ja) | 1998-11-18 | 1999-11-17 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
| US09/856,417 US7300664B1 (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparing same |
| AU11762/00A AU1176200A (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparingsame |
| EP99972096A EP1131052B1 (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparing same |
| PCT/IL1999/000619 WO2000028970A1 (en) | 1998-11-18 | 1999-11-17 | Vaginally administrable progesterone-containing tablets and method for preparing same |
| DK99972096.4T DK1131052T3 (da) | 1998-11-18 | 1999-11-17 | Vaginalt indgivelige progesteron-holdige tabletter og fremgangsmåde til fremstilling deraf |
| US10/832,742 US7393543B2 (en) | 1998-11-18 | 2004-04-26 | Vaginally administratable progesterone-containing tablets and method for preparing same |
| US11/039,062 US7320800B2 (en) | 1998-11-18 | 2005-01-12 | Vaginally administrable progesterone-containing tablets and method for preparing same |
| US11/408,614 US20060188571A1 (en) | 1998-11-18 | 2006-04-20 | Vaginally administrable progesterone containing tablets and method for preparing the same |
| US11/557,036 US20070178139A1 (en) | 1998-11-18 | 2006-11-06 | Vaginally administratable progesterone-containing tablets and method for preparing same |
| JP2010223566A JP2011026335A (ja) | 1998-11-18 | 2010-10-01 | プロゲステロン含有経膣投与用錠剤およびその調製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12712998A IL127129A (en) | 1998-11-18 | 1998-11-18 | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL127129A0 IL127129A0 (en) | 1999-09-22 |
| IL127129A true IL127129A (en) | 2004-06-01 |
Family
ID=11072154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12712998A IL127129A (en) | 1998-11-18 | 1998-11-18 | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US7300664B1 (enExample) |
| EP (2) | EP2386291A1 (enExample) |
| JP (2) | JP4667601B2 (enExample) |
| AU (1) | AU1176200A (enExample) |
| DK (1) | DK1131052T3 (enExample) |
| ES (1) | ES2390959T3 (enExample) |
| IL (1) | IL127129A (enExample) |
| WO (1) | WO2000028970A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| FR2821555B1 (fr) * | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
| KR20050084445A (ko) * | 2002-12-20 | 2005-08-26 | 다이노젠 파마세우티컬스, 인코포레이티드 | α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법 |
| ES2275229T3 (es) * | 2003-03-21 | 2007-06-01 | Dynogen Pharmaceuticals, Inc. | Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio. |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| CA2744906A1 (en) * | 2007-11-29 | 2009-06-04 | Gregg A. Jackson | Progesterone-containing compositions and devices |
| US9107696B2 (en) | 2008-08-06 | 2015-08-18 | Emory University | Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus |
| WO2011073995A2 (en) | 2009-12-14 | 2011-06-23 | Lincoln Pharmaceuticals Limited | Liquid vaginal spray of progesterone |
| FR2997627B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
| CN114129530A (zh) * | 2021-12-08 | 2022-03-04 | 南京康川济医药科技有限公司 | 一种黄体酮缓释组合物及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3121663A (en) | 1956-02-09 | 1964-02-18 | Plough Lab Inc | Carbon dioxide releasing laxative suppository |
| US4252787A (en) * | 1976-12-27 | 1981-02-24 | Cambridge Research And Development Group | Anti-fertility composition and method |
| US4310510A (en) * | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
| US4187286A (en) * | 1979-01-02 | 1980-02-05 | G&W Laboratories, Inc. | Contraceptive suppository |
| US4322399A (en) * | 1979-10-19 | 1982-03-30 | Ortho Pharmaceutical Corporation | Vaginal suppository |
| JPS58152809A (ja) * | 1982-03-05 | 1983-09-10 | Eisai Co Ltd | 安定な発泡性「膣」坐剤 |
| US4583211A (en) * | 1982-06-15 | 1986-04-15 | Tokyo Shibaura Denki Kabushiki Kaisha | Frequency detecting circuit for digital information reproducing system |
| JPS6165822A (ja) * | 1984-09-06 | 1986-04-04 | Kao Corp | 月経困難症治療用膣投与剤 |
| US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
| US5084277A (en) * | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| DK95093D0 (da) * | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| CH689802A5 (de) * | 1995-01-16 | 1999-11-30 | Grapha Holding Ag | Einrichtung zur Vereinzelung von stapelweise zugeführten flachen Gegenständen. |
| US5804277A (en) * | 1995-11-30 | 1998-09-08 | The United States Of America As Represented By The Secretary Of The Air Force | Three-dimensional fiber weave with cubic symmetry and no zero valued shear moduli |
| US5958455A (en) * | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
| US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
| US6306914B1 (en) * | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
| NZ330596A (en) * | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
| FR2772617B1 (fr) | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
| FR2777784B1 (fr) * | 1998-04-27 | 2004-03-19 | Arepa | Composition pharmaceutique a base d'estrogene et de progesterone |
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| US20070178139A1 (en) * | 1998-11-18 | 2007-08-02 | Yankov Vladimir I | Vaginally administratable progesterone-containing tablets and method for preparing same |
| DE102012021570A1 (de) * | 2012-11-02 | 2014-05-22 | Merck Patent Gmbh | Eu-aktivierte Leuchtstoffe |
-
1998
- 1998-11-18 IL IL12712998A patent/IL127129A/en not_active IP Right Cessation
-
1999
- 1999-11-17 WO PCT/IL1999/000619 patent/WO2000028970A1/en not_active Ceased
- 1999-11-17 JP JP2000582018A patent/JP4667601B2/ja not_active Expired - Lifetime
- 1999-11-17 EP EP11166346A patent/EP2386291A1/en not_active Ceased
- 1999-11-17 US US09/856,417 patent/US7300664B1/en not_active Expired - Lifetime
- 1999-11-17 DK DK99972096.4T patent/DK1131052T3/da active
- 1999-11-17 EP EP99972096A patent/EP1131052B1/en not_active Expired - Lifetime
- 1999-11-17 ES ES99972096T patent/ES2390959T3/es not_active Expired - Lifetime
- 1999-11-17 AU AU11762/00A patent/AU1176200A/en not_active Abandoned
-
2004
- 2004-04-26 US US10/832,742 patent/US7393543B2/en not_active Expired - Lifetime
-
2005
- 2005-01-12 US US11/039,062 patent/US7320800B2/en not_active Expired - Lifetime
-
2006
- 2006-04-20 US US11/408,614 patent/US20060188571A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010223566A patent/JP2011026335A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000028970A1 (en) | 2000-05-25 |
| US7300664B1 (en) | 2007-11-27 |
| US20060188571A1 (en) | 2006-08-24 |
| ES2390959T3 (es) | 2012-11-20 |
| JP2002529494A (ja) | 2002-09-10 |
| US7393543B2 (en) | 2008-07-01 |
| JP4667601B2 (ja) | 2011-04-13 |
| US7320800B2 (en) | 2008-01-22 |
| EP1131052B1 (en) | 2012-07-11 |
| DK1131052T3 (da) | 2012-10-15 |
| EP1131052A4 (en) | 2009-04-01 |
| US20050008694A1 (en) | 2005-01-13 |
| JP2011026335A (ja) | 2011-02-10 |
| US20050181045A1 (en) | 2005-08-18 |
| EP2386291A1 (en) | 2011-11-16 |
| AU1176200A (en) | 2000-06-05 |
| IL127129A0 (en) | 1999-09-22 |
| EP1131052A1 (en) | 2001-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011026335A (ja) | プロゲステロン含有経膣投与用錠剤およびその調製法 | |
| CA2470703C (en) | Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
| EP1397133B1 (en) | Rapid onset formulation | |
| Levy et al. | Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction | |
| US10821118B2 (en) | Oral transmucosal drug delivery system | |
| JP2003535015A (ja) | 調整された出血を伴うプロゲスチン治療 | |
| MX2011006106A (es) | Tabletas de acetato de ulipristal. | |
| EP1689372B1 (en) | Compositions for conjugated estrogens and associated methods | |
| AU2001272243A1 (en) | Rapid onset formulation | |
| CN100594936C (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| JPS6344125B2 (enExample) | ||
| EP0335970B1 (en) | Tablet for use in the treatment of progesterone deficiency | |
| JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
| US20070178139A1 (en) | Vaginally administratable progesterone-containing tablets and method for preparing same | |
| CA2568823C (en) | Vaginally administrable progesterone-containing tablets and method for preparing same | |
| TWI239249B (en) | Vaginally administrable progesterone-containing tablets and method for preparing same | |
| JP2023543953A (ja) | 口腔内分散性配合物 | |
| JPS63310817A (ja) | 徐放性バッカル剤の製法 | |
| JPS60248609A (ja) | 口腔粘膜適用徐放性製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |